01
02
Bredin Prat is advising Téthys Invest in connection with the potential acquisition by the private equity firm Warburg Pincus of a stake in the share capital of Sebia, a global leader in in vitro diagnostics, joining Sebia’s existing shareholders CVC Capital Partners, Téthys Invest and La Caisse (formerly called CDPQ).
The Bredin Prat team advising Téthys Invest is as follows: